Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Madrigal intends to use the net proceeds from this offering for its commercial activities in connection with the launch of Rezdiffra (resmetirom), a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH, in the US.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Rezdiffra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $600.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 18, 2024
Details:
Rezdiffra (resmetirom) is a once-daily, oral THR-β agonist designed to target key underlying causes of NASH. It is approved for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Rezdiffra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
MGL-3196 (Resmetirom) is a once-daily, oral, liver-directed THR-β agonist , which is being evaluated for the treatment of NASH/MASH with Liver Fibrosis.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MGL-3196
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
Madrigal will use the proceeds for its clinical and commercial activities in preparation for a potential launch of MGL-3196 (resmetirom), a once daily, oral, thyroid hormone receptor-beta selective agonist designed to target key underlying causes of NASH in the liver.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MGL-3196
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 28, 2023
Details:
MGL-3196 (resmetirom) is a once daily, oral, thyroid hormone receptor (THR)-beta selective agonist designed to target key underlying causes of NASH in the liver.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MGL-3196
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
MGL-3196 (resmetirom), is a once daily, oral, liver-directed selective thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MGL-3196
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
MGL-3196 (resmetirom), is a once daily, oral, liver-directed selective thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MGL-3196
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
MGL-3196 (resmetirom), is a once daily, oral, liver-directed selective thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MGL-3196
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
MGL-3196 (resmetirom) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist designed to improve NASH by increasing hepatic fat metabolism and reducing lipotoxicity. We aimed to assess the safety and efficacy of resmetirom in patients with NASH.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MGL-3196
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hercules Credit Facility
Deal Size: $255.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 21, 2022
Details:
MAESTRO-NASH, a registrational Phase 3 trial, has achieved both liver histological improvement endpoints that FDA proposed as reasonably likely to predict clinical benefit to support accelerated approval for the treatment NASH with liver fibrosis.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MGL-3196
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022